A single arm, Phase II, Open-label Study to determine the efficacy of 100 mg twice daily oral dosing of midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an associated hematological clonal non-mast cell lineage disease

Trial Profile

A single arm, Phase II, Open-label Study to determine the efficacy of 100 mg twice daily oral dosing of midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an associated hematological clonal non-mast cell lineage disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Midostaurin (Primary)
  • Indications Leukaemia; Systemic mastocytosis
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 25 Jun 2017 Pooled survival analysis results comparing clinical data of Midostaurin from D2201 and A2213 studies with historic controls, presented at the 22nd Congress of the European Haematology Association.
    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2017 Planned End Date changed from 10 Jul 2017 to 12 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top